Francois Martelet
Chief Executive Officer
Dr Francois Martelet has a solid late-stage clinical development and commercialization experience from the international pharmaceutical industry, including Merck & Co., Novartis, Schering-Plough, Eli Lilly and Roche. During his time with Merck & Co. (2005-2007), he was Vice President & Worldwide Franchise Head, Oncology, from which position he has gained in-depth knowledge of the HDACi drug class via his role in the global launch of Zolinza. More recently (2007-2009), he was President & CEO of AVAX Technologies, Inc., a US biotech company which is specialized in cancer vaccines therapy. Francois Martelet is a bilingual English/French speaker, and has a command of both German and Swedish. He holds a doctorate with distinction in medicine, a Masters Degree in Business (from the Dijon University of Medicine, Dijon, France), and a degree in legal medicine (Descartes University of Medicine, Paris, France). In addition, he is a graduate of INSEAD (Advanced Management Program) and has attended development programs at Harvard Business School. Francois Martelet is a French national.

Anders Fink Vadsholt
Chief Financial Officer
Mr. Anders Fink Vadsholt has extensive experience from the biotech industry and has most recently been a partner of BankInvest Biomedical Venture which he joined in 2005, and where he was responsible for its investment in TopoTarget. Prior to joining BankInvest Biomedical Venture, he was CFO of several smaller companies, including 7TM Pharma (2000-2002), where he was also a co-founder. He started his career within equity research (life sciences) and corporate finance at Carnegie Bank in Copenhagen. Anders Fink Vadsholt has a M.Sc. in Finance and Commercial Law from CBS, Copenhagen, Denmark; an MBA from University of Melbourne, Melbourne, Australia; and has participated in several management courses, including at Harvard Business School.td>

John Parsons
Chief Commercial Officer & President, TopoTarget USA, Inc.
Mr. Parsons joined Topotarget in 2006 and was named Chief Commercial Officer in September 2007, in charge of global commercial management in addition to his US responsibilities. Mr. Parsons has more than 35 plus years experience from the pharmaceutical industry, overseeing sales, marketing, product development, strategic planning and business execution. Before joining Topotarget, Mr. Parsons founded Parsons Strategic Associates (PSA), a strategic consulting firm focused on the emerging biotechnology industry. Prior to founding PSA, Mr. Parsons held senior management positioned at Innovex, a division of Quintiles, and BASF Pharma (Knoll), where Mr. Parsons was a commercial business manager and a member of the executive committee. Mr. Parsons is a graduate of Indiana University in Bloomington, Ind., and has several advanced certificates of study from the Wharton School of Business at the University of Pennsylvania.

Henri Lichenstein
Chief Development Officer
Dr Lichenstein joined Topotarget in 2009 with over 20 years drug development experience at CuraGen Corporation and Amgen Inc. In his most recent role as Vice President of Product Development, Dr Lichenstein led the Topotarget-CuraGen and NCI alliances in the global clinical development of belinostat. Dr Lichenstein has also led drug discovery and development efforts for a number of protein and monoclonal antibody therapeutics in Oncology and other disease areas, and has led corporate development in- and out-licensing initiatives. Dr Lichenstein has a PhD in Biochemistry and Molecular Biology from the University of California, Santa Barbara and is co-author and inventor on approximately 50 publications and 30 patents, respectively.

Lars Damstrup
Medical Director (CMO ad interim)
Dr Damstrup joined TopoTarget in January 2010 with more than 4 years of drug development experience from Novartis and Genmab in both early and late-stage development. Dr Damstrup has board certification in medical oncology and radiotherapy and has worked for more than 16 years in academia within all major solid tumor types. Before leaving academia, Dr Damstrup headed the GI oncology group at University Hospital in Copenhagen where he was involved in numerous both national and international clinical trials. Dr Damstrup has a PhD in medicine from the University of Copenhagen and has worked more than 6 years in pre-clinical research and is author or co-author on approximately 30 publications.

Elisabeth V. Carstensen
Director of Pharmaceutical Operations
Elisabeth V. Carstensen has been with Topotarget since its very beginning in 2000. Over the years, she has assumed different positions and areas of responsibility in the company. She started as responsible for building and managing the chemistry laboratory, and later she became involved in the pharmaceutical operations with responsibility of managing the supply chain for Savene, Totect, belinostat as well as other products in the clinical pipeline. Elisabeth V. Carstensen was responsible for the CMC area involved in the registration process of Topotarget's first two products on the market, Savene and Totect. Elisabeth V. Carstensen has a background as M.Sc. Chemical Engineering from the Technical University of Denmark from where she also obtained her Ph.D.